Teva Pharmaceutical Industries (TEVA) Depreciation & Amortization (CF) (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Depreciation & Amortization (CF) across 10 years of filings, most recently posting $239.0 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 2.05% year-over-year to $239.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $999.0 million (down 3.1% YoY) and the FY2025 annual result came in at $1.0 billion, down 5.38% from the prior year.
• Depreciation & Amortization (CF) slipped to $239.0 million in Q1 2026, from $260.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $358.0 million in Q2 2022 and troughed at $239.0 million in Q1 2026.
• A 5-year average of $280.2 million and a median of $269.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) increased 17.38% — and 2023, when it decreased 16.2%.
• Tracing TEVA's Depreciation & Amortization (CF) over 5 years: stood at $306.0 million in 2022, then slipped by 13.07% to $266.0 million in 2023, then advanced by 1.13% to $269.0 million in 2024, then dropped by 3.35% to $260.0 million in 2025, then slipped by 8.08% to $239.0 million in 2026.
• Business Quant data shows TEVA's Depreciation & Amortization (CF) at $239.0 million in Q1 2026, $260.0 million in Q4 2025, and $249.0 million in Q3 2025.